Phase III
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 23, 2020.
This morning, the Switzerland-based company said its SPIRIT-2 study met its co-primary efficacy endpoints and six key secondary endpoints for endometriosis treatment.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 22, 2020.
Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology and currently focused on sexual health and pain, is pleased to announce that it has now filed for a further pre-submission meeting with the US FDA following receipt of the complete and signed clinical study report for its Phase 3 Study.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
Results of ibrexafungerp were announced today from the VANISH-306 trial, along with previously announced results from VANISH 303. Here’s more about it.
“We are very pleased with the positive topline data from our global, pivotal Phase III trial of Korsuva Injection, which reinforce the robust results we reported from our U.S. KALM-1 Phase III trial last year,” said Derek Chalmers, president and chief executive officer of Cara.
“The excellent results seen in this Phase III study of 3-month duration suggest that daridorexant can fulfill this significant need for patients with insomnia,” said Dr. Thomas Roth, PhD, Director of the Sleep Disorder and Research Center at Henry Ford Hospital.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 20, 2020.
BMS and Exelixis Eye Potential Approval of RCC Combination Drug Following Positive Phase III Results
This morning, the two companies announced the positive topline results from the pivotal Phase III CheckMate -9ER study in previously untreated patients with renal cell carcinoma.
PRESS RELEASES